| Natural history of benign ethnic neutropenia in individuals of African ancestry R Lakhotia, A Aggarwal, ME Link, GP Rodgers, MM Hsieh Blood Cells, Molecules, and Diseases 77, 12-16, 2019 | 21 | 2019 |
| Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma R Lakhotia, C Melani, K Dunleavy, S Pittaluga, N Saba, L Lindenberg, ... Blood Advances 6 (8), 2667-2680, 2022 | 20 | 2022 |
| Phase 1b/2 study of vipor (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide) in relapsed/refractory B-cell lymphoma: safety, efficacy and molecular analysis C Melani, R Lakhotia, S Pittaluga, MD Miljkovic, JD Phelan, JR Muppidi, ... Blood 136, 44-45, 2020 | 20 | 2020 |
| Next-generation sequencing–based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL MD Miljkovic, C Melani, S Pittaluga, R Lakhotia, N Lucas, A Jacob, ... Blood Advances 5 (20), 4198-4210, 2021 | 15 | 2021 |
| Circulating tumour DNA in B‐cell lymphomas: current state and future prospects R Lakhotia, M Roschewski British Journal of Haematology 193 (5), 867-881, 2021 | 14 | 2021 |
| Circulating tumor DNA dynamics during therapy predict outcomes in mantle cell lymphoma R Lakhotia, C Melani, S Pittaluga, K Dunleavy, NS Saba, AN Lucas, ... Blood 132 (Supplement 1), 147-147, 2018 | 13 | 2018 |
| Phase 1 study of escalating doses of ibrutinib and temozolomide, etoposide, liposomal doxorubicin, dexamethasone, rituximab (TEDDI-R) with isavuconazole for relapsed and … M Roschewski, C Melani, R Lakhotia, S Pittaluga, JD Phelan, C Peer, ... Blood 136, 12-13, 2020 | 10 | 2020 |
| A prospective study of clonal evolution in follicular lymphoma: circulating tumor DNA correlates with overall tumor burden and fluctuates over time without therapy A Distler, R Lakhotia, JD Phelan, S Pittaluga, C Melani, JR Muppidi, ... Blood 138 (Supplement 1), 1328-1328, 2021 | 9 | 2021 |
| Preliminary results of a response-adapted study of ibrutinib and isavuconazole with temozolomide, etoposide, liposomal doxorubicin, dexamethasone, rituximab (TEDDI-R) for … J Simard, C Melani, R Lakhotia, MS Lionakis, S Pittaluga, JD Phelan, ... Blood 136, 24-25, 2020 | 8 | 2020 |
| Incidental 68Ga-DOTATATE uptake in the pancreatic head: A case report and a unique opportunity to improve clinical care R Lakhotia, S Jhawar, AA Malayeri, C Millo, J Del Rivero, MA Ahlman Medicine 99 (22), e20197, 2020 | 8 | 2020 |
| Measurement of circulating tumor DNA to guide management of patients with lymphoma D Sriram, R Lakhotia, TS Fenske Measurement 17 (9), 2019 | 8 | 2019 |
| Clinical presentation and management of primary ovarian neuroendocrine tumor in multiple endocrine neoplasia type 1 S Jhawar, R Lakhotia, M Suzuki, J Welch, SK Agarwal, J Sharretts, ... Endocrinology, diabetes & metabolism case reports 2019 (1), 2019 | 7 | 2019 |
| Phase 2 study of nivolumab in epstein-barr virus (EBV)-positive lymphoproliferative disorders and EBV-positive non-hodgkin lymphomas E Yilmaz, R Lakhotia, S Pittaluga, JR Muppidi, JD Phelan, S Evans, ... Blood 138, 4504, 2021 | 5 | 2021 |
| Phase 1 study of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide in combination with polatuzumab (ViPOR-P) in relapsed/refractory B-cell lymphoma: Preliminary … C Melani, R Lakhotia, S Pittaluga, JD Phelan, J Simard, JR Muppidi, ... Blood 140 (Supplement 1), 6602-6603, 2022 | 4 | 2022 |
| Phase 2 study of ibrutinib with temozolomide, etoposide, liposomal doxorubicin, dexamethasone, rituximab (TEDDI‐R) for secondary CNS lymphoma M Roschewski, J Simard, C Melani, R Lakhotia, JD Phelan, S Pittaluga, ... Hematological Oncology 41, 44-46, 2023 | 3 | 2023 |
| Phase 1b/2 study of vipor (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide) in relapsed/refractory and untreated mantle cell lymphoma: safety, efficacy, and … C Melani, R Lakhotia, S Pittaluga, MD Miljkovic, JD Phelan, JR Muppidi, ... Blood 138, 3537, 2021 | 3 | 2021 |
| Phase 2 study of acalabrutinib window prior to frontline therapy in untreated aggressive B-cell lymphoma: Preliminary results and correlatives of response to acalabrutinib M Roschewski, JD Phelan, S Pittaluga, C Melani, R Lakhotia, JJ Chabon, ... Blood 138, 524, 2021 | 2 | 2021 |
| Phase Ib/II Study of Multi-Targeted Therapy with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) Diffuse Large B-Cell … C Melani, R Lakhotia, S Pittaluga, JD Phelan, G Wright, J Simard, ... Blood 142, 434, 2023 | 1 | 2023 |
| Phase I study of response-adapted treatment with venetoclax, obinutuzumab, and magrolimab (Venom) in relapsed and refractory indolent B-cell Malignancies R Lakhotia, C Melani, S Pittaluga, JD Phelan, A Pradhan, A Tadese, ... Blood 142, 6172, 2023 | 1 | 2023 |
| Phase 2 Response-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, and Rituximab (TEDDI-R) for Secondary CNS Lymphoma J Simard, JD Phelan, C Melani, R Lakhotia, S Pittaluga, JR Muppidi, ... Blood 142, 854, 2023 | 1 | 2023 |
